Send us a Text Message.

Today’s topic is the The Federal NOPAIN Act.

The Federal “Non-Opioids Prevent Addiction In the Nation Act” (or, the “NOPAIN Act”), Senate bill S.586, was signed into law in December 2022. It takes effect this coming January as part of the Centers for Medicare and Medicaid Services 2025 OPPS proposed rule.

The NOPAIN Act directs CMS to reimburse hospital and surgical centers separately for non-opioid, post-surgical pain control, in hopes of reducing or replacing opioid consumption. By separating, or “unbundling,” payment for non-opioid pain control, hospitals and surgical centers may receive additional reimbursement for non-opioid alternatives, encouraging the use of substitute means of pain control. This helps to ensure that non-opioid options are more widely available to individuals as a post-surgical treatment option.

You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/

Or, feel free to email us at Insights@thekinetixgroup.com

Send us a Text Message.

The High-Value Pharmacy Enterprise Framework.

The High-Value Pharmacy Enterprise Framework is a collection of evidence-based and expert recommended best practices designed to enhance health system pharmacy operations by ensuring safe, effective, and patient-centered medication management throughout the health-system pharmacy enterprise. It is gaining in popularity due to the many patient safety, operational, and cost efficiencies it brings to health systems that embrace the model.

The HVPE framework is built around 8 Domains of essential pharmacy practice elements that are established best practices for health-system pharmacies. The framework contains a total of 94 operational statements and 336 performance measures within these 8 domains.

You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/

Or, feel free to email us at Insights@thekinetixgroup.com

Send us a Text Message.

Introduction to Targeted Therapies: Monoclonal Antibodies

Targeted Therapy is the foundation of Precision Medicine. Targeted therapy is a type of personalized treatment that targets specific proteins that control how cells grow, divide, and spread.

Antibodies are produced naturally by our body and help the immune system recognize cells that cause disease, such as bacteria and viruses, and mark them for destruction. Antibodies can be engineered in the laboratory to find and attach themselves to specific targets, called antigens, found on cancer cells. They are made to recognize and bind only to a very specific antigen target.

This week's episode highlights three important terms you may be hearing: Antibody-Drug Conjugates, Monoclonal Antibodies, and Bispecific Antibodies.

You can download the full Executive Briefing at: https://tkgpact.com/executive-briefings/

Or, feel free to email us at Insights@thekinetixgroup.com